Read this manager's filing book
Disclosed positions
TCG Crossover Management, LLC: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- ABIVAX SA AMERICAN DEPOSITARY SHARES
- Ticker
- ABVX
- Class
- COMM
- Reported value
- $800,603,959
- Reported amount
- 6,007,834
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001214659-26-010290Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| ABIVAX SA AMERICAN DEPOSITARY SHARES | ABVX | COMM | $800,603,959 | 6,007,834 | SH | None |
| TANGO THERAPEUTICS INC | TNGX | COMM | $283,878,343 | 9,081,201 | SH | None |
| CG ONCOLOGY INC | CGON | COMM | $260,768,136 | 3,670,206 | SH | None |
| COGENT BIOSCIENCES INC | COGT | COMM | $187,866,673 | 4,854,436 | SH | None |
| IMMUNOVANT INC | IMVT | COMM | $171,766,278 | 4,457,988 | SH | None |
| SPYRE THERAPEUTICS INC | SYRE | COMM | $168,733,670 | 1,900,582 | SH | None |
| DIANTHUS THERAPEUTICS INC | DNTH | COMM | $163,437,308 | 1,676,624 | SH | None |
| MIRUM PHARMACEUTICALS INC | MIRM | COMM | $124,334,076 | 1,062,049 | SH | None |
| ZAI LAB LTD-ADR | ZLAB | ADRS | $116,614,913 | 6,137,627 | SH | None |
| AMYLYX PHARMACEUTICALS INC | AMLX | COMM | $112,138,864 | 6,243,812 | SH | None |
| MONTE ROSA THERAPEUTICS INC | GLUE | COMM | $111,856,054 | 4,622,151 | SH | None |
| BIOCRYST PHARMACEUTICALS INC | BCRX | COMM | $110,209,680 | 11,020,968 | SH | None |
| VOR BIOPHARMA INC | VOR | COMM | $104,441,366 | 5,673,078 | SH | None |
| TYRA BIOSCIENCES INC | TYRA | COMM | $103,772,421 | 3,248,980 | SH | None |
| DYNE THERAPEUTICS INC | DYN | COMM | $102,502,348 | 4,615,144 | SH | None |
| DISC MEDICINE INC | IRON | COMM | $98,143,787 | 1,341,862 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COMM | $79,954,491 | 4,273,356 | SH | None |
| SAVARA INC | SVRA | COMM | $76,151,183 | 12,362,205 | SH | None |
| AURA BIOSCIENCES INC | AURA | COMM | $67,686,664 | 9,533,333 | SH | None |
| REVOLUTION MEDICINES INC | RVMD | COMM | $63,843,565 | 340,899 | SH | None |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | COMM | $58,253,516 | 2,895,304 | SH | None |
| KODIAK SCIENCES INC | KOD | COMM | $56,318,161 | 1,445,538 | SH | None |
| AVALO THERAPEUTICS INC | AVTX | COMM | $55,756,378 | 3,017,120 | SH | None |
| LB PHARMACEUTICALS INC | LBRX | COMM | $46,972,446 | 1,447,310 | SH | None |
| CENTURY THERAPEUTICS INC | IPSC | COMM | $43,401,690 | 17,754,430 | SH | None |
| TECTONIC THERAPEUTIC INC | TECX | COMM | $41,418,128 | 1,204,891 | SH | None |
| XENCOR INC | XNCR | COMM | $39,479,422 | 2,452,138 | SH | None |
| SURROZEN INC | SRZN | COMM | $38,226,971 | 1,473,101 | SH | None |
| EDITAS MEDICINE INC | EDIT | COMM | $36,000,000 | 11,111,111 | SH | None |
| MBX BIOSCIENCES INC | MBX | COMM | $35,880,000 | 650,000 | SH | None |
| PHARVARIS BV | PHVS | COMM | $34,864,559 | 1,008,229 | SH | None |
| SILENCE THERAPEUTICS PLC | SLN | ADRS | $33,308,489 | 3,033,560 | SH | None |
| INFLARX N V | Unresolved | COMM | $32,480,000 | 14,500,000 | SH | None |
| ALTIMMUNE INC | ALT | COMM | $30,400,000 | 10,000,000 | SH | None |
| JANUX THERAPEUTICS INC | JANX | COMM | $27,488,517 | 1,789,617 | SH | None |
| PERSPECTIVE THERAPEUTICS INC | CATX | COMM | $26,992,083 | 7,915,567 | SH | None |
| AGOMAB THERAPEUTICS NV | AGMB | ADRS | $26,650,964 | 2,053,233 | SH | None |
| BIOHAVEN LTD | BHVN | COMM | $26,485,686 | 1,779,952 | SH | None |
| AKTIS ONCOLOGY INC | AKTS | COMM | $22,450,129 | 696,560 | SH | None |
| ALECTOR INC | ALEC | COMM | $20,100,000 | 10,000,000 | SH | None |
| FORTE BIOSCIENCES INC | FBRX | COMM | $19,550,000 | 920,000 | SH | None |
| MONOPAR THERAPEUTICS INC | MNPR | COMM | $18,826,047 | 203,327 | SH | None |
| OCULAR THERAPEUTIX INC | OCUL | COMM | $16,180,925 | 1,647,752 | SH | None |
| ADC THERAPEUTICS SA | ADCT | COMM | $12,187,487 | 11,390,175 | SH | None |
| ALX ONCOLOGY HOLDINGS INC | ALXO | COMM | $11,706,858 | 5,655,487 | SH | None |
| ENTRADA THERAPEUTICS INC | TRDA | COMM | $7,803,293 | 1,060,230 | SH | None |
| CULLINAN THERAPEUTICS INC | CGEM | COMM | $7,407,573 | 406,786 | SH | None |
| ARVINAS HOLDING CO LLC | ARVN | COMM | $5,875,984 | 707,098 | SH | None |
| KORRO BIO INC | KRRO | COMM | $5,486,847 | 416,301 | SH | None |
| RESEARCH ALLIANCE CORP CL A | Unresolved | COMM | $5,350,000 | 500,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 3 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.